trending Market Intelligence /marketintelligence/en/news-insights/trending/uvpgtcwuej4k8auypva1fq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Halozyme appoints former Bristol-Myers exec to board

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Halozyme appoints former Bristol-Myers exec to board

Halozyme Therapeutics Inc., a San Diego-based biotechnology company, appointed Bernadette Connaughton to its board.

Connaughton most recently worked with Bristol-Myers Squibb Co. as an intercontinental president for a region that included China, Latin America, Central and Eastern Europe and the Middle East. In this role, she developed the commercialization strategy for a number of products, including Opdivo, Yervoy, Sprycel, Daklinza and Orencia.

Halozyme researches, develops and commercializes human enzymes and other drug candidates in the U.S. and Switzerland, and internationally.